Last reviewed · How we verify
SMOFlipid
SMOFlipid provides essential fatty acids for energy production, membrane structure, and bioactive molecule synthesis.
At a glance
| Generic name | SMOFlipid |
|---|---|
| Also known as | SMOF, MOFS lipid emulsion, Total parenteral nutrition, SMOFLIPID (mixture of soy, fish, MCT and olive oil), Parenteral nutrition (PN) |
| Sponsor | Baylor College of Medicine |
| Drug class | Lipid Emulsion [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
SMOFlipid supplies fatty acids that are crucial for generating energy through beta oxidation, maintaining cell membrane integrity, and producing bioactive molecules like prostaglandins. These fatty acids also play a role in regulating gene expression.
Approved indications
Common side effects
- nausea
- vomiting
- hyperglycemia
- flatulence
- pyrexia
- abdominal pain
- blood triglycerides increased
- hypertension
- sepsis
- dyspepsia
- urinary tract infection
- anemia
Key clinical trials
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
- Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients (PHASE4)
- SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury
- LIPIDS-P Trial Phase I/II Trial (PHASE1, PHASE2)
- Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates (PHASE3)
- Intralipid Versus SMOFlipid in HPN Patients (NA)
- Diagnostic Role of the "White Test" With Lipidic Solution in the Early Intraoperative Identification of Open Bile Ducts for the Prevention of Bile Leakage After Liver Resection (BiLe -Trial) (PHASE3)
- Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |